- Home
- WLAC vs BDTX Comparison
WLAC vs BDTX Comparison
Compare WLAC & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- BDTX
- Stock Information
- Founded
- WLAC 2024
- BDTX 2014
- Country
- WLAC United States
- BDTX United States
- Employees
- WLAC N/A
- BDTX N/A
- Industry
- WLAC
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLAC
- BDTX Health Care
- Exchange
- WLAC Nasdaq
- BDTX Nasdaq
- Market Cap
- WLAC 172.6M
- BDTX 181.4M
- IPO Year
- WLAC 2024
- BDTX 2020
- Fundamental
- Price
- WLAC $10.84
- BDTX $3.17
- Analyst Decision
- WLAC
- BDTX Strong Buy
- Analyst Count
- WLAC 0
- BDTX 6
- Target Price
- WLAC N/A
- BDTX $12.50
- AVG Volume (30 Days)
- WLAC 253.3K
- BDTX 836.3K
- Earning Date
- WLAC 01-01-0001
- BDTX 11-04-2025
- Dividend Yield
- WLAC N/A
- BDTX N/A
- EPS Growth
- WLAC N/A
- BDTX N/A
- EPS
- WLAC N/A
- BDTX 0.25
- Revenue
- WLAC N/A
- BDTX $70,000,000.00
- Revenue This Year
- WLAC N/A
- BDTX N/A
- Revenue Next Year
- WLAC N/A
- BDTX N/A
- P/E Ratio
- WLAC $734.67
- BDTX $12.66
- Revenue Growth
- WLAC N/A
- BDTX N/A
- 52 Week Low
- WLAC $9.80
- BDTX $1.20
- 52 Week High
- WLAC $11.15
- BDTX $6.23
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- BDTX 59.42
- Support Level
- WLAC N/A
- BDTX $3.13
- Resistance Level
- WLAC N/A
- BDTX $3.43
- Average True Range (ATR)
- WLAC 0.00
- BDTX 0.17
- MACD
- WLAC 0.00
- BDTX 0.03
- Stochastic Oscillator
- WLAC 0.00
- BDTX 64.86
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.